Company logo

PALI - Palisade Bio, Inc.

NASDAQ -> Healthcare -> Biotechnology
Carlsbad, United States
Type: Equity

PALI price evolution
PALI
(in millions $) 29 Jul 2022 30 Apr 2022 31 Jan 2022 29 Oct 2021
Current assets
Cash
Short term investments
Net receivables $0.02 $0.09
Inventory
Total current assets $7.42 $8.26 $12.37 $16.09
Long term investments
Property, plant & equipment $0.36 $0.07 $0.11 $0.16
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $7.81 $8.35 $12.51 $16.27
Current liabilities
Accounts payable $1.04 $1.15 $1.32 $1.38
Deferred revenue
Short long term debt
Total current liabilities $2.86 $1.86 $2.5 $2.92
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $3.6 $3.56 $5.15 $12.35
Shareholders' equity
Retained earnings -$101.19 -$98.85 -$94.64 -$95.72
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Current assets
Cash
Short term investments
Net receivables $0.15 $0.12 $0.02 $0.36
Inventory
Total current assets $12.37 $12.88 $5.65 $6.51
Long term investments
Property, plant & equipment $0.11 $0.01 $0.04 $0.09
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $12.51 $13.05 $6.58 $7.68
Current liabilities
Accounts payable $1.32
Deferred revenue
Short long term debt
Total current liabilities $2.5 $3.21 $1.22 $1.05
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $5.15 $3.28 $1.46 $1.63
Shareholders' equity
Retained earnings -$94.64 -$238.24 -$221.98 -$213.62
Other shareholder equity -$0.01
Total shareholder equity
(in millions $) 29 Jul 2022 30 Apr 2022 31 Jan 2022 29 Oct 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $3.57 $3.89 $4.03 $3.02
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $1.22 $0.79 $5.09 $12.74
Net income
Net income -$2.34 -$4.21 $1.07 $8.09
Income (for common shares)
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Revenue
Total revenue $0.01 $0.02 $0.26
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $11.74 $10.69 $8.65 $8.52
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $20.64 $0.03 $0.56 $3.34
Net income
Net income -$26.62 -$16.27 -$8.35 -$4.92
Income (for common shares)
(in millions $) 29 Jul 2022 30 Apr 2022 31 Jan 2022 29 Oct 2021
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.05 -$0.05
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $1.5 -$0.09 $24.61 $25.16
Effect of exchange rate
Change in cash and equivalents -$5.52 -$3.85 $9.78 $13.39
(in millions $) 31 Jan 2022 31 Jan 2021 31 Jan 2020 31 Jan 2019
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.05 $5
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $24.61 $14.47 $6.59 $1.81
Effect of exchange rate -$0.01 -$0.01
Change in cash and equivalents $9.78 $5.44 -$0.68 -$0.89
Fundamentals
Market cap $82.05M
Enterprise value N/A
Shares outstanding 21.88M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income $2.61M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio 31.42
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS $0.12
ROA 23.24%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 2.59
Quick ratio N/A